Vimian Group ABVIMGF 76 EBITDA Margin % is 26.98% as of Mar. 2026, which is 28% above its 10-year median of 21.07. GuruFocus rates VIMGF with a GF Score™ of 76/100 and a GF Value™ of $3.24. The stock has 2 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Vimian Group AB ranks better than 82.35% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Vimian Group AB's EBITDA for the
three
months ended in Mar. 2026 was $36.2 Mil. Vimian Group AB's Revenue for the
three
months ended in Mar. 2026 was $134.1 Mil. Therefore, Vimian Group AB's EBITDA margin for the quarter that ended in Mar. 2026 was 26.98%.
Vimian Group AB (OTCPK:VIMGF) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Vimian Group AB EBITDA Margin % Related Terms
Vimian Group AB EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Vimian Group AB's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VIMGF vs TMO, DHR, IDXX: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Vimian Group AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vimian Group AB EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Vimian Group AB's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Vimian Group AB's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vimian Group AB (VIMGF) has a EBITDA Margin % of 26.98% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Vimian Group AB and its competitors. This is 28% above median its historical median of 21.07. According to the industry distribution chart, Vimian Group AB ranks #36 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 17.6%.
Is Vimian Group AB's EBITDA Margin % too high?
Vimian Group AB's current EBITDA Margin % of 26.98% is 28% above median its 10-year median of 21.07. The Medical Diagnostics & Research industry median EBITDA Margin % is 5.20. Vimian Group AB's value of 26.98% is 418.8% above this industry median. Based on the distribution chart, Vimian Group AB ranks #36 out of 204 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Vimian Group AB has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.
How does Vimian Group AB's EBITDA Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Vimian Group AB ranks #36 out of 204 companies for EBITDA Margin %. This places Vimian Group AB in the top 18% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 5.20. Vimian Group AB's value of 26.98% is 418.8% above this benchmark. While the company's 10-year median is 21.07 vs. the industry median of 5.20, Vimian Group AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.20, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vimian Group AB's current EBITDA Margin % of 26.98% is 418.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Vimian Group AB and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vimian Group AB's current EBITDA Margin % is 26.98%, which is 28% above median its own 10-year median of 21.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vimian Group AB stock overvalued right now?
Vimian Group AB (VIMGF) has a current EBITDA Margin % of 26.98%. The stock's GF Value™ is $3.24, compared to a current price of $2.77 — trading 14.5% below its estimated fair value. The current EBITDA Margin % is 26.98%, which is 28% above median its 10-year median of 21.07 and 418.8% above the Medical Diagnostics & Research industry median of 5.20. Vimian Group AB's overall GF Score™ is 76/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Vimian Group AB (VIMGF), the current EBITDA Margin % is 26.98% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vimian Group AB (VIMGF) Overvalued in 2026?
Based on GuruFocus' analysis, Vimian Group AB stock appears to be undervalued.
The current stock price of $2.77 is trading 14.5% below its estimated GF Value™ of $3.24.
Key valuation signals for VIMGF:
EBITDA Margin %: 26.98% (28% above median its 10-year median of 21.07)
GF Value™: $3.24 vs. price of $2.77 (14.5% below fair value)
Industry Position: 418.8% above the Medical Diagnostics & Research median (#36 of 204)
No single metric tells the full story. See the VIMGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vimian Group AB specializes in the areas of animal health, such as specialty pharma, diagnostics, medtech, and veterinary services. It offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals, with a position within allergy, dermatology, otology, and specialized nutrition. Its geographical segments include Europe, North America, and the Rest of the world.
76GF Score
Get the complete analysis for VIMGF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VIMGF has been successfully added to your 
